Form 8-K Ocuphire Pharma, Inc. For: Mar 27
Ocuphire Pharma, Inc. (OCUP)
Company Research
Source: SEC EDGAR
Impact Snapshot
Event Time:
OCUP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OCUP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OCUP alerts
High impacting Ocuphire Pharma, Inc. news events
Weekly update
A roundup of the hottest topics
OCUP
News
- UPDATE – Ocuphire Pharma Initiates VEGA-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% for Presbyopia [Yahoo! Finance]Yahoo! Finance
- UPDATE – Ocuphire Pharma Initiates VEGA-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% for PresbyopiaGlobeNewswire
- Ocuphire Pharma Initiates VEGA-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% for PresbyopiaGlobeNewswire
- Ocuphire Pharma, Inc. (NASDAQ:OCUP) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates [Yahoo! Finance]Yahoo! Finance
- Ocuphire Pharma, Inc. (NASDAQ: OCUP) had its price target lowered by analysts at HC Wainwright from $20.00 to $18.00. They now have a "buy" rating on the stock.MarketBeat
OCUP
Earnings
- 8/13/24 - Miss
OCUP
Analyst Actions
- 8/14/24 - Canaccord Genuity
OCUP
Sec Filings
- 8/13/24 - Form 10-Q
- 8/13/24 - Form 8-K
- OCUP's page on the SEC website